{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:24:04Z","timestamp":1783056244432,"version":"3.54.6"},"reference-count":40,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer\u2010term (104 weeks) efficacy and safety results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with active AS were randomized to subcutaneous secukinumab 150 mg, 75 mg, or placebo at baseline; weeks 1, 2, and 3; and every 4 weeks from week 4. The primary end point was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16. Other end points included ASAS40, high\u2010sensitivity C\u2010reactive protein, ASAS5\/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form 36 health survey physical component summary, ASAS partial remission, EuroQol 5\u2010domain measure, and Functional Assessment of Chronic Illness Therapy fatigue subscale. End points were assessed through week 104, with multiple imputation for binary variables and a mixed\u2010effects model repeated measures for continuous variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 219 randomized patients, 60 of 72 (83.3%) and 57 of 73 (78.1%) patients completed 104 weeks of treatment with secukinumab 150 mg and 75 mg, respectively; ASAS20\/ASAS40 response rates at week 104 were 71.5% and 47.5% with both secukinumab doses, respectively. Clinical improvements with secukinumab were sustained through week 104 across all secondary end points. Across the entire treatment period (mean secukinumab exposure 735.6 days), exposure\u2010adjusted incidence rates for serious infections and infestations, Crohn's disease, malignant or unspecified tumors, and major adverse cardiac events with secukinumab were 1.2, 0.7, 0.5, and 0.7 per 100 patient\u2010years, respectively. No cases of tuberculosis reactivation, opportunistic infections, or suicidal ideation were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab provided sustained improvement through 2 years in the signs and symptoms of AS, with a safety profile consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.23233","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T17:26:44Z","timestamp":1487957204000},"page":"1020-1029","source":"Crossref","is-referenced-by-count":84,"title":["Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study"],"prefix":"10.1002","volume":"69","author":[{"given":"H.","family":"Marzo\u2010Ortega","sequence":"first","affiliation":[{"name":"Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sieper","sequence":"additional","affiliation":[{"name":"University Clinic Benjamin Franklin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla, \u200bInstituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2010IDIVAL\u200b Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"McGill University Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Readie","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Richards","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Measure 2 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"147","article-title":"Quality indicators, guidelines and outcome measures in ankylosing spondylitis","volume":"25","author":"Zochling J","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041129"},{"key":"e_1_2_8_4_1","first-page":"965","article-title":"Anti\u2010TNF\u2010\u03b1 treatment and spondyloarthropathies","volume":"141","author":"Braun Y","year":"2002","journal-title":"Harefuah"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2005.43319"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32816a938c"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.7"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_24_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","unstructured":"EuroQol: a new facility for the measurement of health\u2010related quality of life. Health Policy1990;16:199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201601"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150117"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1928-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20233"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.06.002"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513488501"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.993378"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8276-8"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22669"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:57:38Z","timestamp":1759420658000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/acr.23233"],"URL":"https:\/\/doi.org\/10.1002\/acr.23233","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727343690.793550507","asserted-by":"object"}]},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}